Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Clinical Insights into...
Imunitní trombocytopenie – zajímavosti z ASH®
11 septembra, 2020 7:51 pmV rámci každoročního kongresu Americké hematologické společnosti, který se konal ve dnech 7.–10. prosince 2019 v Orlandu na Floridě (Spojené státy americké) bylo prezentováno...
The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 632. Chronic Myeloid Leukemia: Therapy: Poster I Hematology Disease Topics & Pathways:...
RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 632. Chronic Myeloid Leukemia: Therapy: Response Monitoring and Prognosis ...
Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes ...
Chronická myelocytová leukémia – novinky z výročnej konferencie ASH® 2019
11 septembra, 2020 7:51 pmŠesťdesiata prvá výročná konferencia Americkej hematologickej spoločnosti (posledná v tomto desaťročí) – v skratke ASH® 2019 – sa konala od 7. do 10. 12....
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 704. Immunotherapies II Hematology Disease Topics & Pathways: Diseases,...
Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies:...
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell...
NOVINKY Z ASH® – AGRESÍVNE LYMFÓMY
11 septembra, 2020 7:51 pmV plenárnej sekcii boli prezentované výsledky štúdie fázy 1/1b GO2971, skúmajúcej bezpečnosť a účinnosť mosunetuzumabu v liečbe pacientov s relabovaným alebo refraktérnym difúznym veľkobunkovým...